Henderson B W, Bellnier D A
Division of Radiation Biology, Roswell Park Memorial Institute, Buffalo, NY 14263.
Ciba Found Symp. 1989;146:112-25; discussion 125-30. doi: 10.1002/9780470513842.ch8.
This paper outlines our present knowledge of photosensitizer tissue distribution, derived from preclinical animal studies, and relates it to the observed biological response to photodynamic therapy (PDT). Emphasis is placed on porphyrins (haematoporphyrin derivative (HpD), Photofrin II) and phthalocyanines (aluminum phthalocyanine sulphonate AlPcS). In mice, both groups of sensitizers show multiphasic plasma clearance kinetics with an initial rapid decline followed by further slow reduction. Residual amounts of Photofrin II are detectable 75 days after injection. Drug elimination occurs through urine and faeces, but faecal elimination predominates for Photofrin II. Circulating sensitizer greatly influences the mouse ear-swelling response, but not the foot response. Tumours and normal skin can be destroyed by vascular damage, if illumination occurs at times of maximal plasma sensitizer concentration, with no detectable sensitizer accumulation in tumour cells. Organ retention for both photosensitizer groups is similar and persistent. Organs rich in reticuloendothelial elements (liver, kidney, spleen) accumulate and retain the highest levels, skin and muscle the lowest, while normal brain tissue excludes sensitizer. The adrenal and pancreatic glands, as well as urinary bladder, also retain high amounts of Photofrin II. Tumour/skin ratios of 1 to 3:1 and 2 to 7:1 have been reported for porphyrins and sulphonated phthalocyanines respectively. Tissue destruction upon light exposure is not always correlated with photosensitizer levels, as is exemplified by liver and pancreas. Stromal sensitizer localization usually predominates in tumour and normal tissue, and often determines tumour response. Certain compounds, such as monosulphonated tetraphenylporphyrin and AlPcS, may favour parenchymal localization. The formed blood elements remain free of photosensitizer, while mast cells and macrophages accumulate especially large amounts and, upon illumination, release an array of vasoactive inflammatory and immune mediators.
本文概述了我们目前从临床前动物研究中获得的关于光敏剂组织分布的知识,并将其与观察到的光动力疗法(PDT)的生物学反应相关联。重点放在卟啉(血卟啉衍生物(HpD)、光卟啉II)和酞菁(磺化铝酞菁AlPcS)上。在小鼠中,这两类光敏剂均呈现多相血浆清除动力学,起初迅速下降,随后进一步缓慢降低。注射75天后仍可检测到光卟啉II的残留量。药物通过尿液和粪便排出,但光卟啉II以粪便排出为主。循环中的光敏剂对小鼠耳部肿胀反应有很大影响,但对足部反应无影响。如果在血浆光敏剂浓度最高时进行光照,肿瘤和正常皮肤可因血管损伤而被破坏,肿瘤细胞中未检测到光敏剂积累。两类光敏剂在器官中的潴留情况相似且持久。富含网状内皮细胞的器官(肝脏、肾脏、脾脏)积累和潴留的水平最高,皮肤和肌肉最低,而正常脑组织则排除光敏剂。肾上腺、胰腺以及膀胱也潴留大量的光卟啉II。据报道,卟啉和磺化酞菁的肿瘤/皮肤比率分别为1至3:1和2至7:1。光照后组织破坏并不总是与光敏剂水平相关,肝脏和胰腺就是例证。基质光敏剂定位在肿瘤和正常组织中通常占主导,且常常决定肿瘤反应。某些化合物,如单磺化四苯基卟啉和AlPcS,可能有利于实质定位。血细胞中没有光敏剂,而肥大细胞和巨噬细胞积累的光敏剂特别多,光照后会释放一系列血管活性炎症和免疫介质。